Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
暂无分享,去创建一个
J. Shah | M. Gonen | J. Fagin | R. Ghossein | R. Tuttle | A. Shaha | R. Leboeuf | H. Tala | M. Brokhin | Gal Omry
[1] P. Ladenson,et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.
[2] I. Hay. Management of patients with low-risk papillary thyroid carcinoma. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[3] N. Nagelkerke,et al. A note on a general definition of the coefficient of determination , 1991 .
[4] E. Vignali,et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens , 2003, Annals of Internal Medicine.
[5] T. Pilli,et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. , 2008, The Journal of clinical endocrinology and metabolism.
[6] Spencer Ca. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. , 2000 .
[7] Shinichiro,et al. Carcinoma , 1906, The Hospital.
[8] J. Shah. Exploiting biology in selecting treatment for differentiated cancer of the thyroid gland , 2008, European Archives of Oto-Rhino-Laryngology.
[9] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[10] R. Kloos,et al. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. , 2005, The Journal of clinical endocrinology and metabolism.
[11] B. Lang,et al. Staging Systems for Papillary Thyroid Carcinoma: A Review and Comparison , 2007, Annals of surgery.
[12] E. Mazzaferri. Management of low-risk differentiated thyroid cancer. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[13] M. van Glabbeke,et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.
[14] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[15] R. Kloos,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .
[16] P. Arveux,et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[18] A. Pinchera,et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[19] C. Spencer. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[20] Kwang-Yoon Jung,et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.
[21] Stephanie L. Lee,et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[22] J. Shah,et al. Risk group stratification and prognostic factors in papillary carcinoma of thyroid , 1996, Annals of Surgical Oncology.
[23] Tuttle Rm. Risk-Adapted Management of Thyroid Cancer , 2008 .
[24] M. Luster,et al. A comparison of prognostic classification systems for differentiated thyroid carcinoma , 2009, Clinical endocrinology.
[25] J. Fagin,et al. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. , 2009, Current Opinion in Cell Biology.
[26] R. Tuttle. Risk-adapted management of thyroid cancer. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[27] Mark Dowar,et al. Influence of age and primary tumor size on the risk for residual/recurrent well‐differentiated thyroid carcinoma , 2009, Head & neck.
[28] B. O'Sullivan,et al. A comparison of different staging systems predictability of patient outcome , 1997, Cancer.
[29] J. Shah,et al. Low-risk differentiated thyroid cancer: The need for selective treatment , 1997, Annals of Surgical Oncology.